

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP			
2. Address Address1 <u>1800 CONCORD PIKE, P.O. BOX 15437</u> Address2 _____ City <u>WILMINGTON</u> State <u>DE</u> Zip Code <u>19850-5437</u> Country <u>USA</u>			
3. Principal place of business (if different than line 2) City _____ State _____ Zip Code _____ Country _____			
4a. Contact Name Ms. <u>Sarah Arbes</u>	b. Telephone Number <u>2022467003</u>	c. E-mail <u>sarah.arbes@astrazeneca.com</u>	5. Senate ID# <u>54073-12</u>
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP			6. House ID# <u>349750000</u>

TYPE OF REPORT 8. Year 2025 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center">12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,240,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Sarah Arbes Date 4/21/2025 3:00:06 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R.946 - Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act
 HR 1262/ S 932, Give Kids A Chance Act
 Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language)
 Issues related to Inflation Reduction Act (IRA) consideration of small molecule drugs, biologics, and genetically targeted technologies
 Issues related to expanding/amending the orphan drug exclusion in IRA
 Issues related to pharmacy benefit manager (PBM) reform
 Issues related to e-labeling
 Issues related to the price and manufacture of inhaled medicines
 Issues related to the IRAs drug price negotiation program
 Issues related to drug pricing
 Issues related to the US manufacturing of pharmaceuticals
 Issues related to importation of drugs
 Issues related to FDA Orange Book patent listings
 Issues related to environmental sustainability
 Issues related to FDA modernization
 Policies related to international reference pricing for pharmaceuticals
 Policies related to 340B rebate model for IRA compliance
 Policies related to the definition of a qualifying single source drug under the IRA
 Pediatric rare disease priority review voucher
 Reauthorization of the pediatric priority review voucher program
 Company sustainability policy issues
 General issues related to health equity in rare disease and clinical trials
 General issues related to vaccine safety, efficacy, and access
 General issues related to rare disease and orphan drugs
 General issues related to ACIP recommendations
 Education to Hill staff on next generation propellant and PFAS
 FDA modernization policy issues
 Tariffs/trade policies related to tariffs on pharmaceuticals

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>
Lisa	Langenderfer			<input type="checkbox"/>
Emily	Mace		Intern, Rep. Bruce Westerman (AR-4); Legislative Assistant & Counsel, Rep. Bruce Westerman (AR-4); Senior Policy Advisor & Counsel, Rep. H. Morgan Griffith (VA-9); Deputy Chief of Staff & Counsel, Rep. Larry Bucshon (IN-8)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Definition of Qualified Single Source Drug (QSSD) for purposes of Medicare drug price negotiation
 E-labeling - allowing FDA to finalize a rule to allow digital versions of prescriptions
 Medicare patient access to rare disease therapies
 Centers for Medicare and Medicaid Innovation (CMMI) policy issues
 Value-based payment arrangements
 Efforts to improve coding, coverage, and access for rare disease therapies
 Medicare drug price negotiation
 Part B and Part D drugs
 Medicare Part D reform and inflation penalties
 Medicaid Drug Rebate Program proposed rule
 Issues related to the digital communication of prescribing information for drugs
 General issues related to diagnostic reimbursement

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>
Lisa	Langenderfer			<input type="checkbox"/>
Emily	Mace		Intern, Rep. Bruce Westerman (AR-4); Legislative Assistant & Counsel, Rep. Bruce Westerman (AR-4); Senior Policy Advisor & Counsel, Rep. H. Morgan Griffith (VA-9); Deputy Chief of Staff & Counsel, Rep. Larry Bucshon (IN-8)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

e-labeling- allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers
 Issues related to PBM reform
 US manufacturing of pharmaceuticals

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>
Lisa	Langenderfer			<input type="checkbox"/>
Emily	Mace		Intern, Rep. Bruce Westerman (AR-4); Legislative Assistant & Counsel, Rep. Bruce Westerman (AR-4); Senior Policy Advisor & Counsel, Rep. H. Morgan Griffith (VA-9); Deputy Chief of Staff & Counsel, Rep. Larry Bucshon (IN-8)	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R.591 - Defending American Jobs and Investment Act
 HR 1414 - Cameron's Law, to restore orphan drug research tax credit
 H.R.1990 - American Innovation and R&D Competitiveness Act of 2025
 H.R.4695 - Unfair Tax Prevention Act
 Expiring provisions of the Tax Cut and Jobs Act law
 Tax reform in budget reconciliation
 Trade and tariffs (general education, country-specific tariffs, sector-specific tariffs)
 pharmaceutical manufacturing (general education)
 Issues related to tariffs
 Issues related to the deduction of research and development expenditures
 Education on tax in preparation for 2025 tax legislation

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>
Lisa	Langenderfer			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to IP and patents
Issues related to FDA Orange Book patent listings

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1	_____	_____	3	_____	_____
2	_____	_____	4	_____	_____

ISSUE UPDATE

24. General lobbying issue that no longer pertains

INS

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)		
	Street Address						
	City	State/Province	Zip	Country	City	State	Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address					
	City	State/Province	Country	City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------